MyFinsight
Home
Blog
About
Back
Cash Flow
Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. (DCOY)
source: myfinsight.com
Proceeds from issuance of
equity securities, net
$3,162,943
Net cash provided by
financing activities
$3,162,943
Net decrease in cash
$468,500
Canceled cashflow
$2,694,443
Equity-based compensation
$206,177
Depreciation and
amortization
$13,632
Net cash used in
operating activities
-$2,652,019
Net cash used in
investing activities
-$42,424
Canceled cashflow
$219,809
Net loss
-$2,373,800
Accounts payable
-$230,614
Deferred revenue
-$227,629
Purchase of fixed assets
$42,424
Accrued expenses and
other
-$28,759
Prepaid expenses and
other current assets
$11,026
Back